LEO 35299

Drug Profile

LEO 35299

Alternative Names: LEO-35299

Latest Information Update: 10 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LEO Pharma
  • Class Antipsoriatics
  • Mechanism of Action CXCR4 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Psoriasis

Most Recent Events

  • 30 Jun 2012 LEO Pharma completes a phase I trial in Psoriasis in France (NCT01580488)
  • 30 Apr 2012 Phase-I clinical trials in Psoriasis in France (Topical)
  • 20 Aug 2009 Preclinical development in Psoriasis in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top